SKIP000966
SKIP ID SKIP000966
Organism(En) -
Organism(Ja) -
Cell Type(En) -
Cell Type(Ja) -
Cell Tissue(En) -
Cell Tissue(Ja) -
Cell Origin Diseased
Cell Name 1(En) PDB1lox-21GFP-19
Cell Name 1(Ja) PDB1lox-21GFP-19
Cell Name 2(En) -
Cell Name 2(Ja) -
Disease Name 1(Ja) パーキンソン病
ICD Code 1 G20
Disease Name 1(En) Parkinson disease
OMIM1 168600
Disease Name 2(Ja) -
ICD Code 2 -
Disease Name 2(En) -
OMIM 2 -
Disease Name 3(Ja) -
ICD Code 3 -
Disease Name 3(En) -
OMIM 3 -
Age 53
Age Range 50-59
Sex Male
Race(En) -
Race(Ja) -
Genetic Diagnosis Yes
Not Detected No
Description(En) Human iPSCs were established from AG20442 fibroblasts.
In order to derive hiPSCs that were free of proviruses, estabulishers generated lentiviral vectors that could be excised after integration using Cre-recombinase. The human ubiquitin promoter of the FUGW-loxP lentivirus, which contains a loxP site in the 30 long terminal repeat (LTR), was replaced with a DOX-inducible, minimal cytomegalovirus (CMV) promoter followed by the human cDNAs for OCT4, KLF4, or SOX2. Upon proviral replication, the loxP site in the 30 LTR is duplicated into the 50 LTR, resulting in an integrated transgene flanked by loxP sites in both LTRs.
Such a Cre-loxP system worked on this iPSC line, resulting in reprogramming factors were removed.
iPSC lines, PDB^x, were established from the same person.
Description(Ja) 皮膚線維芽細胞(AG20442)より樹立したヒト人工多能性幹細胞 (iPSC) 株。
ウイルス由来の導入遺伝子を排除したiPSC株を作製するために樹立者らはCre-recombinaseを用いてゲノムインテグレーションを排除するレンチウイルスベクターを作製した。30 LTRにloxPを含むFUGW-loxPレンチウイルスのヒトユビキチンプロモーターはヒトcDNA(OCT4, KLF4, or SOX2)をもつドキシサイクリン誘導性CMVプロモーターに置換される。ウイルス複製の際に、30 LTRのloxPサイトは50 LTRに複製される。結果的に導入遺伝子は両LTRの間に配置される。
本株は上記のシステムを稼働させ、初期化因子を排除したものである。
PDB^xは同一人由来のクローン株。
Cell Morphology human ES-like
Grade Research Grade
Vector Lentivirus
Transgene FUWtetO-loxP lentiviral vectors transducing three reprogramming factors, OCT4, KLF4, and SOX2.
(Reprogramming factors were removed by Cre-recombinase.)
Adhesiveness -
Feeder Yes
Feeder Cell mitomycin C (MMC)-inactivated mouse embryonic fibroblast (MEF) feeder layers
Medium hESC medium (DMEM/F12 [Invitrogen] supplemented with 15% FBS [Hyclone], 5% KnockOut Serum Replacement [Invitrogen], 1 mM glutamine [Invitrogen], 1% nonessential amino acids [Invitrogen], 0.1 mM β-mercaptoethanol [Sigma], and 4 ng/ml FGF2 [R&D Systems])
Genome Editing pTurbo-Cre+pEGFP
CO2 -
Mycoplasma -
Detection of Contaminants Mycoplasma -
Pluripotent Markers Yes
Pluripotent Markers Assay immunocytochemistry
in vitro Differentiation Yes
in vitro Differentiation Assay differentiation to dopmainargic neuron
in vivo Differentiation Yes
in vivo Differentiation Assay teratoma formation
Other 1 Assay -
Other 1 Assay Method -
Other 2 Assay -
Other 2 Assay Method -
Other 3 Assay -
Other 3 Assay Method -
Karyotype Yes
Karyotype Assay -
Remaining Vector Detection Yes
Remaining Vector Detection Assay Southern blot analysis
STR -
HLA -
Stem Cell Transcriptome analysis Yes
Stem Cell Transcriptome analysis Assay qRT-PCR
Author Name(En) Rudolf Jaenisch
Author Name(Ja) Rudolf Jaenisch
Author Organization(En) The Whitehead Institute
Author Organization(Ja) The Whitehead Institute
Author Contact Email -
PI Organization(En) The Whitehead Institute
PI Organization(Ja) The Whitehead Institute
PI Name(En) Rudolf Jaenisch
PI Name(Ja) Rudolf Jaenisch
PI Contact Email -
Availability Available
Provider Organization(En) The Whitehead Institute
Provider Organization(Ja) The Whitehead Institute
Provider Email jaenisch[at]wi[dot]mit[dot]edu
Provider URL -
Ethical Statement(En) -
Ethical Statement(Ja) -
Terms of Use(En) -
Terms of Use(Ja) -
PubMed ID 19269371
DOI 10.1016/j.cell.2009.02.013
Title Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.
Authors Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R
Journal Cell
Year 2009
Volume 136
Issue 5
Pages 964-77
URL http://www.ncbi.nlm.nih.gov/pubmed/19269371
Free input -
Note -